Second Quarter 2010 -- Selected Highlights: Financial: •Soliris® (eculizumab) net product sales increased 36 percent to $125.8 million in Q2 2010, compared to $92.3 million in Q2 2009.
Second Quarter 2010 -- Selected Highlights: Financial: •Soliris® (eculizumab) net product sales increased 36 percent to $125.8 million in Q2 2010, compared to $92.3 million in Q2 2009.